A 12-year perspective on the world's first total laryngeal transplant

Transplantation

Volumn 91, Issue 7, 2011, Pages 804-805

  Knott, P Daniel ^a   Hicks, Douglas ^a   Braun, William ^a   Strome, Marshall ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b New York Head & Neck Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS;

ALLOTRANSPLANTATION; BONE DENSITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPIGLOTTITIS; FEMUR NECK; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; LARYNGECTOMY; LARYNX TRANSPLANTATION; LETTER; LUMBAR SPINE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; SIDE EFFECT; VOICE;

BONE DENSITY; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LARYNX; POSTOPERATIVE COMPLICATIONS;

EID: 79954571988     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31820cfd0b     Document Type: Letter

References (14)

1. Lorenz RR, Hicks DM, Shields RW Jr, et al. Laryngeal nerve function after total laryngeal transplantation. Otolaryngol Head Neck Surg 2004; 131: 1016.
2. Strome M, Stein J, Escalamdo R, et al. Laryngeal transplantation and 40-month follow-up. N Engl J Med 2001; 344: 1676.
3. Birchall MA, Lorenz RR, Berke GS, et al. Laryngeal transplantation in 2005: A review. Am J Transplant 2006; 6: 20.
4. Birchall MA, Macchiarini P. Airway transplantation: A debate worth having? Transplantation 2008; 85: 1075.
5. Khariwala SS, Kjaergaard J, Lorenz RR, et al. Everolimus (RAD) inhibits in vivo growth of murine squamous cell carcinoma (SCC VII). Laryngoscope 2006; 116: 814.
6. Knott PD, Tamai H, Strome M, et al. RAD inhibition of sarcoma growth: Implications for laryngeal transplantation.AmJ Otolaryngol 2007; 28: 375.
7. Shipchandler TZ, Lorenz RR, Lee WT, et al. Laryngeal transplantation in the setting of cancer: A rat model. Laryngoscope 2008; 118: 2166.
8. Khariwala SS, Knott PD, Dan O, et al. Pulsed Immunosuppression with everolimus and anti-alphabeta T-cell receptor: Laryngeal allograft preservation at six months. Ann Otol Rhinol Laryngol 2006; 115: 74.
9. Lott DG, Dan O, Lu L, et al. Long-term allograft survival using low-dose everolimus. Otolaryngol Head Neck Surg 2010; 142: 72.
10. Arichi N, Kishikawa H, Nishimura K, et al. Malignancy following kidney transplantation. Transplant Proc 2008; 40: 2400.
11. Schena NP, Pascoe MD, Alberu J, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009; 87: 233.
12. Lopez V, Gutierrez C, Cabello M, et al. Conversion to sirolimus in posttransplant renal neoplasms. Transplant Proc 2007; 39: 2264.
13. Katada A, Van Himbergen D, Kunibe I, et al. Evaluation of a deep brain stimulation electrode for laryngeal pacing. Ann Otol Rhinol Laryngol 2008; 117: 621.
14. Eliachar I, Akst LM, Eliashar R. Unaided speech in tube-free tracheostomy: The supplementary sling procedure. Otolaryngol Head Neck Surg 2002; 127: 213.